Under TA875, Wegovy is recommended as an option for weight management in adults when prescribed in specialist weight management services with: At least one weight-related comorbidity Initial BMI of at least 35 kg/m (or lower thresholds of 30 kg/m for people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean family backgrounds) Treatment duration is typically limited to a maximum of 2 years in NHS settings
As weight decreases and fitness improves, graduated activity becomes safer and often more sustainable
Severe gastrointestinal conditions Conditions like gastroparesis (delayed stomach emptying) may be worsened by GLP-1 medications, which slow gastric motility further
GLP-1 helps regulate blood sugar levels and promotes satiety, while Peptide YY reduces appetite and slows down the digestive process
Where there is reduced access to GLP-1 RAs, support people with type 2 diabetes to access structured education and weight management programmes where available, it said
For the best outcome and safety, always consult a healthcare professional before preparing your dose